Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines

被引：51

作者：

Anderson, Kenneth C. ^{[1
]}

Alsina, Melissa ^{[2
]}

Atanackovic, Djordje ^{[3
]}

Biermann, J. Sybil ^{[4
]}

Chandler, Jason C. ^{[5
]}

Costello, Caitlin ^{[6
]}

Djulbegovic, Benjamin ^{[2
]}

Fung, Henry C. ^{[7
]}

Gasparetto, Cristina ^{[8
]}

Godby, Kelly ^{[9
]}

Hofmeister, Craig ^{[10
,11
]}

Holmberg, Leona ^{[12
]}

Holstein, Sarah ^{[13
]}

Huff, Carol Ann ^{[14
]}

Kassim, Adetola ^{[15
]}

Krishnan, Amrita Y. ^{[16
]}

Kumar, Shaji K. ^{[17
]}

Liedtke, Michaela ^{[18
]}

Lunning, Matthew ^{[19
]}

Raje, Noopur ^{[20
]}

Reu, Frederic J. ^{[21
,22
]}

Singhal, Seema ^{[23
]}

Somlo, George ^{[16
]}

Stockerl-Goldstein, Keith ^{[24
,25
]}

Treon, Steven P. ^{[1
]}

Weber, Donna ^{[26
]}

Yahalom, Joachim ^{[27
]}

Shead, Dorothy A. ^{[28
]}

Kumar, Rashmi ^{[28
]}

机构：

[1] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[4] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[5] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[6] UC San Diego Moores Canc Ctr, San Diego, CA USA

[7] Fox Chase Canc Ctr, Philadelphia, PA USA

[8] Duke Canc Inst, Durham, NC USA

[9] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA

[10] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[11] Solove Res Inst, Columbus, OH USA

[12] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA

[13] Roswell Pk Canc Inst, Buffalo, NY USA

[14] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[15] Vanderbilt Ingram Canc Ctr, Franklin, TN USA

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Mayo Clin Canc Ctr, Rochester, MN USA

[18] Stanford Canc Inst, Stanford, CA USA

[19] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[20] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[21] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[22] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[23] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[24] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[25] Washington Univ, Sch Med, St Louis, MO 63130 USA

[26] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[27] Mem Sloan Kettering Canc Ctr, New York, NY USA

[28] Natl Comprehens Canc Network, New York, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2016年 / 14卷 / 04期

关键词：

ORAL PROTEASOME INHIBITOR; PANOBINOSTAT PLUS BORTEZOMIB; INTERNATIONAL STAGING SYSTEM; LOW-DOSE DEXAMETHASONE; INDUCTION THERAPY; PHASE-II; LENALIDOMIDE; COMBINATION; CYCLOPHOSPHAMIDE; CARFILZOMIB;

D O I：

10.6004/jnccn.2016.0046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

These NCCN Guidelines Insights highlight the important updates/changes specific to the 2016 version of the NCCN Clinical Practice Guidelines in Oncology for Multiple Myeloma. These changes include updated recommendations to the overall management of multiple myeloma from diagnosis and staging to new treatment options.

引用

页码：389 / 400

页数：10

共 37 条

[11] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma [J].

Dytfeld, Dominik ;

Jasielec, Jagoda ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi ;

Jakubowiak, Andrzej J. .

HAEMATOLOGICA, 2014, 99 (09) :E162-E164

[12] International staging system for multiple myeloma [J].

Greipp, PR ;

San Miguel, J ;

Durie, BGM ;

Crowley, JJ ;

Barlogie, B ;

Bladé, J ;

Boccadoro, M ;

Child, JA ;

Harousseau, JL ;

Kyle, RA ;

Lahuerta, JJ ;

Ludwig, H ;

Morgan, G ;

Powles, R ;

Shimizu, K ;

Shustik, C ;

Sonneveld, P ;

Tosi, P ;

Turesson, I ;

Westin, J .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3412-3420

[13] CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma [J].

Hsi, Eric D. ;

Steinle, Roxanne ;

Balasa, Balaji ;

Szmania, Susann ;

Draksharapu, Aparna ;

Shum, Benny P. ;

Huseni, Mahrukh ;

Powers, David ;

Nanisetti, Amulya ;

Zhang, Yin ;

Rice, Audie G. ;

van Abbema, Anne ;

Wong, Melanie ;

Liu, Gao ;

Zhan, Fenghuang ;

Dillon, Myles ;

Chen, Shihao ;

Rhodes, Susan ;

Fuh, Franklin ;

Tsurushita, Naoya ;

Kumar, Shankar ;

Vexler, Vladimir ;

Shaughnessy, John D., Jr. ;

Barlogie, Bart ;

van Rhee, Frits ;

Hussein, Mohamad ;

Afar, Daniel E. H. ;

Williams, Marna B. .

CLINICAL CANCER RESEARCH, 2008, 14 (09) :2775-2784

[14] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Nordgren, Brian ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi .

BLOOD, 2012, 120 (09) :1801-1809

[15]

Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21254, 10.3322/caac.21332, 10.3322/caac.21551, 10.3322/caac.20073, 10.3322/caac.21387, 10.3322/caac.21654, 10.3322/caac.21601]

[16]

Jimenez Zepeda VH, 2014, BLOOD, V124, P5751, DOI DOI 10.1182/BLOOD.V124.21.5751.5751

[17] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib [J].

Kumar, S. K. ;

LaPlant, B. ;

Roy, V. ;

Reeder, C. B. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Laumann, K. ;

Thompson, M. A. ;

Witzig, T. E. ;

Buadi, F. K. ;

Rivera, C. E. ;

Mikhael, J. R. ;

Bergsagel, P. L. ;

Kapoor, P. ;

Hwa, L. ;

Fonseca, R. ;

Stewart, A. K. ;

Chanan-Khan, A. ;

Rajkumar, S. V. ;

Dispenzieri, A. .

BLOOD CANCER JOURNAL, 2015, 5 :e338-e338

[18] Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma [J].

Kumar, Shaji ;

Flinn, Ian ;

Richardson, Paul G. ;

Hari, Parameswaran ;

Callander, Natalie ;

Noga, Stephen J. ;

Stewart, A. Keith ;

Turturro, Francesco ;

Rifkin, Robert ;

Wolf, Jeffrey ;

Estevam, Jose ;

Mulligan, George ;

Shi, Hongliang ;

Webb, Iain J. ;

Rajkumar, S. Vincent .

BLOOD, 2012, 119 (19) :4375-4382

[19]

Kumar SK, 2015, BLOOD, V126

[20] Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study [J].

Kumar, Shaji K. ;

Berdeja, Jesus G. ;

Niesvizky, Ruben ;

Lonial, Sagar ;

Laubach, Jacob P. ;

Hamadani, Mehdi ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Roy, Vivek ;

Vescio, Robert ;

Kaufman, Jonathan L. ;

Berg, Deborah ;

Liao, Eileen ;

Di Bacco, Alessandra ;

Estevam, Jose ;

Gupta, Neeraj ;

Hui, Ai-Min ;

Rajkumar, Vincent ;

Richardson, Paul G. .

LANCET ONCOLOGY, 2014, 15 (13) :1503-1512

← 1 2 3 4 →